Full-Time
Director of Pharmacovigilance & Safety
Posted on 6/4/2026
Hippocratic AI
201-500 employees
Licenses safety-focused healthcare LLMs to institutions
No salary listed
Palo Alto, CA, USA
In Person
 Biology & Biotech (1) |
|---|
- 7-15 years of experience in pharmacovigilance, drug safety, or clinical safety within pharma, biotech, CRO, or life sciences services organizations — with progressive responsibility for PV system design, case processing operations, and regulatory compliance.
- Deep expertise in global pharmacovigilance regulations including FDA regulations, EMA GVP, ICH guidelines, MedDRA coding, and safety reporting requirements across major markets.
- Direct experience building or significantly expanding PV operations — not just maintaining inherited systems but designing processes, standing up case management infrastructure, and establishing quality standards.
- Demonstrated ability to engage credibly with pharma PV, safety, quality, and regulatory stakeholders at senior levels — including experience leading or participating in safety audits, PVA negotiations, and vendor qualification processes.
- Strong understanding of the end-to-end AE lifecycle from detection through regulatory submission, including ICSR processing, signal detection, aggregate reporting, and risk management.
- Ability to translate PV requirements into technical specifications and product requirements — working effectively with engineering and data science teams to embed safety capabilities into technology platforms.
- Comfort working in high-growth environments with limited structure and high expectations for ownership, innovation, and cross-functional collaboration.
- Exceptional written and verbal communication skills with the ability to make complex safety and regulatory concepts accessible to both customers and internal non-PV teams.
- Pharmacovigilance System Design and Operations: Design and build the company's pharmacovigilance infrastructure from the ground up — creating the processes, systems, and governance frameworks for how AI-driven patient interactions are monitored for adverse events, product complaints, and safety signals.
- Pharmacovigilance System Design and Operations: Define how adverse events are detected, captured, classified, documented, and reported within AI agent conversations — developing the logic, language models, and escalation rules that enable real-time AE identification at scale across therapeutic areas and product types.
- Pharmacovigilance System Design and Operations: Develop and operationalize end-to-end AE processing workflows including intake, triage, case assessment, MedDRA coding, causality evaluation, narrative authoring, regulatory submission, and follow-up — adapted for the unique characteristics of AI-generated interactions.
- Pharmacovigilance System Design and Operations: Build and maintain a safety case database and quality management system that meets regulatory standards and supports audit readiness across FDA, EMA, and other global regulatory authorities.
- Pharmacovigilance System Design and Operations: Establish aggregate safety reporting capabilities including PSURs, PADERs, DSURs, and ad hoc safety analyses as required by pharma partners and regulatory obligations.
- Pharmacovigilance System Design and Operations: Define SLAs, quality metrics, and performance standards for the PV operation — including case processing timelines, data quality benchmarks, and compliance KPIs.
- Pharmacovigilance System Design and Operations: Develop and manage safety escalation pathways that ensure medically significant events are routed immediately to qualified medical reviewers, regardless of time or volume.
- Safety Signal Detection and Innovation: Design and implement safety signal detection capabilities that leverage the unique advantages of AI-driven patient engagement — including the ability to analyze millions of structured conversations for emerging safety patterns that traditional PV methods would miss.
- Safety Signal Detection and Innovation: Develop frameworks for proactive safety monitoring that go beyond regulatory minimums — using platform interaction data to identify potential signals earlier, with greater sensitivity, and across broader patient populations than conventional passive surveillance.
- Safety Signal Detection and Innovation: Partner with Engineering and Data Science to build automated signal detection tools, trend analysis dashboards, and anomaly detection models that provide real-time visibility into the safety profile of every product the platform supports.
- Safety Signal Detection and Innovation: Explore and pioneer new approaches to AI-enabled pharmacovigilance — including natural language processing for AE detection, predictive safety modeling, patient-reported outcome integration, and real-world safety evidence generation.
- Safety Signal Detection and Innovation: Publish and present on innovations in AI-enabled PV, establishing Hippocratic AI as a thought leader in the future of drug and device safety.
- Customer-Facing Safety and PV Partnership: Serve as the company's primary safety and PV authority in all customer-facing contexts — including enterprise deal cycles, vendor qualification reviews, safety audits, and ongoing partnership governance.
- Customer-Facing Safety and PV Partnership: Engage directly with pharma and medtech partner PV, safety, quality, and regulatory teams to demonstrate the platform's safety capabilities, AE handling processes, and compliance infrastructure.
- Customer-Facing Safety and PV Partnership: Develop customer-facing PV documentation including safety management plans, PV agreements (PVAs), safety data exchange agreements (SDEAs), reconciliation processes, and audit-readiness materials that meet the standards pharma partners require from qualified safety vendors.
- Customer-Facing Safety and PV Partnership: Support Sales and Customer Success by providing safety and PV credibility that differentiates Hippocratic AI from competitors and accelerates deal cycles — particularly with pharma organizations where PV qualification is a gating factor in vendor selection.
- Customer-Facing Safety and PV Partnership: Participate directly in customer safety audits, inspections, and governance reviews — representing the company's PV posture with the depth and confidence that pharma safety leaders expect.
- Customer-Facing Safety and PV Partnership: Navigate customer-specific safety requirements across therapeutic areas — understanding that PV expectations for an oncology supportive care program differ meaningfully from those for a diabetes device onboarding program or a post-surgical follow-up workflow.
- Regulatory Compliance and Global Safety Standards: Ensure all pharmacovigilance operations comply with applicable global regulations including FDA 21 CFR Parts 312/314, EMA GVP Modules, ICH E2B(R3), ICH E2D, MedDRA standards, and applicable local regulations across deployment geographies.
- Regulatory Compliance and Global Safety Standards: Develop and maintain pharmacovigilance SOPs, work instructions, and training materials that reflect current regulatory requirements and industry best practices.
- Regulatory Compliance and Global Safety Standards: Monitor and interpret evolving PV regulations and guidance — including FDA's approach to AI in safety monitoring, EMA expectations for digital health pharmacovigilance, and emerging global standards for AI-enabled safety systems — and advise leadership on their implications.
- Regulatory Compliance and Global Safety Standards: Partner with Legal and Compliance to ensure safety data handling meets HIPAA, GDPR, and industry-specific privacy requirements, particularly around patient health information captured during AI interactions.
- Regulatory Compliance and Global Safety Standards: Prepare and maintain regulatory inspection readiness — ensuring the PV operation can withstand FDA, EMA, or partner-initiated audits at any time.
- Platform Integration and Engineering Partnership: Partner with Engineering and Product to embed pharmacovigilance logic directly into the AI platform — ensuring that AE detection, safety escalation, and case capture are built into the conversation architecture rather than layered on as post-processing.
- Platform Integration and Engineering Partnership: Define safety requirements and acceptance criteria for new platform features, conversation flows, and therapeutic area deployments — ensuring every patient-facing capability is evaluated through a PV lens before launch.
- Platform Integration and Engineering Partnership: Work with Engineering to build safety monitoring dashboards, real-time alerting systems, and automated case processing tools that enable the PV operation to scale alongside platform growth.
- Platform Integration and Engineering Partnership: Collaborate with the Data Science team on training and validating AI models for AE detection accuracy, ensuring false negative rates for safety events meet or exceed the performance of human-operated PV systems.
- Platform Integration and Engineering Partnership: Contribute to the company's overall clinical governance framework alongside Medical Affairs — ensuring safety is integrated into the broader medical quality and oversight structure.
- Experience with AI, digital health, or technology platforms in a pharmacovigilance or safety capacity
- Advanced degree in life sciences, pharmacy, nursing, or medicine (PharmD, PhD, MD, MSN, MPH) strongly preferred
- Familiarity with safety database systems (e.g., Argus, ArisG, Veeva Vault Safety) and experience with system selection, configuration, or migration
- Experience with medical device vigilance, complaint handling, and post-market surveillance in addition to drug safety
- Qualified Person for Pharmacovigilance (QPPV) designation or equivalent experience
- Startup or early-stage company experience
- Certification in pharmacovigilance or drug safety is a plus
- What We're Looking For: A pharmacovigilance leader who sees this moment for what it is — the chance to reinvent how drug and device safety operates in an era of AI-driven patient engagement, and to be the person who writes the playbook the industry follows. A systems builder who can design PV infrastructure from first principles, not just replicate what exists elsewhere, because what exists elsewhere wasn't built for a world where AI agents conduct patient interactions at scale. A customer-facing safety authority who gives pharma PV and quality leaders the confidence to say yes — because you speak their language, you've sat in their audits, and you know what their inspectors will ask. A creative thinker who looks at the data flowing through millions of AI-patient conversations and sees not just a compliance obligation but an unprecedented opportunity to detect safety signals faster, with greater precision, and at a scale that traditional PV has never achieved. An engineering-minded safety leader who can work with data scientists and developers to build AE detection and signal monitoring capabilities that push the entire field forward. A builder who wants to define what pharmacovigilance looks like when AI is the front line — and who understands that getting safety right isn't just a regulatory requirement, it's the foundation everything else is built on.
Hippocratic AI develops specialized language models for healthcare, licensing them to hospitals and clinics to improve patient care and operational efficiency. The models are trained on evidence-based medical content and refined with a Reinforcement Learning with Human Feedback process involving healthcare professionals to ensure safety and accuracy. Unlike general-purpose LLMs, its focus on safety, equity, bedside manner, and real-world deployment differentiates it from competitors. The goal is to improve healthcare access, equity, and outcomes by providing safe, reliable AI tools for providers and patients.
Company Size
201-500
Company Stage
Series C
Total Funding
$402M
Headquarters
Palo Alto, California
Founded
2022
Simplify's Take
What believers are saying
- Advocate Health reached 15,000 hypertension patients and closed about 1,200 care gaps.
- Polaris 5.0 adds multilingual voice switching, expanding reach across diverse patient populations.
- Recent partnerships with UNC Health and Cincinnati Children's validate enterprise demand.
What critics are saying
- General-purpose frontier labs are rapidly improving healthcare voice and safety tooling.
- Healthcare deployments depend on script review, consent language, and workflow governance.
- Any public safety, privacy, or escalation failure damages a safety-first brand immediately.
What makes Hippocratic AI unique
- Safety-focused healthcare LLMs target non-diagnostic patient conversations, not general-purpose chat.
- Polaris uses 180 million+ clinical interactions and 7,500+ licensed clinicians for validation.
- AI Front Door and Nurse Co-Pilot address access and inpatient nursing workflows.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Hippocratic AI who can refer or advise you
Benefits
Remote Work Options
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 1%1 year growth
↑ 0%2 year growth
↑ 1%Hippocratic AI launches two industry firsts: AI Front Door and Nurse Co-Pilot to expand clinical care and access. PR Newswire Today at 11:30am PDT PR Newswire PALO ALTO, Calif., Apr. 16, 2026 The first safe, omni-topic Voice AI for patient access, including inbound calls and the first AI voice assistant built for inpatient nurses - giving healthcare leaders the tools to move from scarcity to abundance PALO ALTO, Calif., Apr. 16, 2026 /PRNewswire/ - Hippocratic AI today announced two new Voice AI products that mark a turning point in how healthcare organizations deliver care: AI Front Door, a safe, always-available AI health agent that replaces fragmented call centers and digital front doors with a single, continuous patient relationship over multiple calls, delivering omni-topic care across all patient needs; and Nurse Co-Pilot, the first AI voice assistant built specifically for inpatient nurses, co-developed with Cincinnati Children's Hospital Medical Center, OhioHealth, and Cleveland Clinic, designed to return 1-4 hours of nursing per shift. Both products are powered by Hippocratic AI's patented Polaris safety architecture - with 180+ million patient interactions, 99.90% correct clinical advice, 0.00% severe harm events, and validation from 7,500+ U.S.-licensed clinicians. "For all of healthcare's history, care has been designed around the assumption of scarcity," said Munjal Shah, CEO and co-founder of Hippocratic AI. "AI Front Door and Nurse Co-Pilot change that equation. One gives every patient a personal health agent. The other gives every nurse an AI assistant. Together, they put healthcare leaders in control of a shift from scarcity to abundance." AI FRONT DOOR: ONE AGENT. EVERY NEED. EVERY CHANNEL. The "digital front door" promised access but delivered phone trees, long hold times, and disconnected experiences. AI Front Door replaces this with a single intelligent agent that resolves needs in one continuous conversation instead of deflecting them. Omni-topic. A patient can schedule an appointment, ask about lab results, address a billing issue, and follow up on care instructions, all in one conversation, no transfers, no restarts. Relationship-based. Every interaction builds on the last. The AI remembers patient history, preferences, and prior conversations, shifting the experience from transactional to longitudinal. Less call center, more care. Patient advocate. AI Front Door prepares patients before visits, follows up afterward, and closes care gaps in between - serving as a continuous member advocate, guiding members through benefits, preparing them for appointments, and keeping care plans on track. Operates externally - It doesn't stop at answering questions. The AI coordinates referrals, arranges transportation, contacts employers, and manages the logistics that typically fall through the cracks. Omnichannel. Start on the phone, continue over text, finish in the app - one seamless conversation that never loses context. Caregiver in the loop. Whether a patient has a caregiver or is one, AI Front Door keeps everyone connected - authorizations, status updates, and care discussions, all coordinated. "Every time a patient calls, that's a window of engagement, even if the initial call is just to reset a password. Most systems squander it - transfers, hold times, callbacks. AI Front Door doesn't. It resolves the need right there, powered by 31 coordinated LLM models that can safely navigate any topic, from scheduling to clinical needs in a single conversation." - Vishal Parikh, Chief Product Officer, Hippocratic AI. AI Front Door is already being deployed with initial partners, including Wellspan and Cincinnati Children's with more healthcare leaders coming on board this month. NURSE CO-PILOT: THE FIRST AI BUILT FOR BEDSIDE NURSES, BY NURSES While most healthcare AI has focused on physician documentation and administrative workflows, nurses, the largest segment of the clinical workforce, have seen little of that investment. Nurse Co-Pilot is designed to take work away from nurses, not pile more on. Co-developed with nursing leaders at Cincinnati Children's, OhioHealth, and Cleveland Clinic, it launches with four critical inpatient workflows: Admission Education - Walks newly admitted patients through what to expect, giving nurses time back for hands-on care. Patient Education - Delivers consistent education throughout the stay, from disease management to discharge preparation. Caregiver Engagement - Prepares family members for life after discharge: medications, warning signs, follow-ups, daily routines. The education that prevents readmissions. Medication Adherence - Walks patients through every medication so they leave informed and adherent. Each workflow, if executed by a nurse, will take from 10-15 minutes. By deploying Nurse Co-Pilot, the result can be 1-4 hours returned per nurse, per shift, depending on usage back to direct patient care. How it works: A nurse launches Nurse Co-Pilot directly from the EHR, selects the patient and workflow, and the AI calls the patient by phone - no app download required. After the call, a structured clinical summary and full transcript are written back to the EHR automatically. The nurse triggers every call, reviews every result, and maintains full clinical oversight. The AI is the tool; the nurse is the clinician. "There's never been enough time in a shift to reach every patient the way you want to," said Amy McCarthy, Chief Nursing Officer, Hippocratic AI. "Nurse Co-Pilot gives nurses an AI assistant that ensures every patient gets the follow-up they need, while giving nurses time back for hands-on care." ABOUT HIPPOCRATIC AI Hippocratic AI is building the safety layer for healthcare AI. The company's patented Polaris safety architecture ensures that AI agents in healthcare meet the highest standards of clinical safety, validated by licensed healthcare professionals. Founded by Munjal Shah, the company is headquartered in Palo Alto, California. For more information, visit hippocraticai.com. SOURCE Hippocratic AI This is a paid placement. For further inquiries, please contact PR Newswire directly.
Hippocratic AI consolidates Life Sciences leadership with acquisition of Grove AI and key executive appointments. The move establishes a dedicated Life Sciences Division and senior executive advisory council to accelerate generative AI across the biopharma and medtech value chain. PALO ALTO, Calif. - (BUSINESS WIRE) - #GenAI - Hippocratic AI, the global leader and pioneer in patient-facing generative AI healthcare agents, today announced a major expansion of its life sciences business. The company has acquired Grove AI, appointed a President of Life Sciences, launched a world-class Life Sciences Executive Advisory Council, and entered into a strategic collaboration with Boston Consulting Group (BCG). Together, these milestones establish Hippocratic AI as the category leader in deploying safe, scalable, and clinically grounded generative AI across the biopharma and medtech value chain, from R&D and clinical trials to commercialization and post-market patient engagement. "Real impact in the life sciences sector requires deeply specialized models, exhaustive safety testing, and LLM safety architectures built to operate within highly regulated environments," said Munjal Shah, Co-founder and CEO of Hippocratic AI. "That is why Hippocratic AI has strategically expanded its life sciences leadership - acquiring Grove AI, appointing a dedicated President of Life Sciences, convening a world-class Executive Advisory Council, and partnering with Boston Consulting Group." Hippocratic AI's generative AI agents are powered by its proprietary Polaris safety architecture, delivering high-fidelity clinical reasoning and enterprise-grade auditability at scale. Backed by more than 150 million clinical interactions to date and following its recent $126M Series C financing, with a portion of proceeds earmarked for M&A, the company is continuing to scale production-ready generative AI agents that life sciences organizations can trust across research, clinical, and patient engagement workflows. Acquisition of Grove AI to Accelerate Clinical Engagement Capabilities Hippocratic AI has acquired Grove AI, a leader in agentic AI for pharma R&D and clinical trial operations, uniting two teams aligned around a shared vision of healthcare abundance, expanding access, accelerating research, and removing friction across the life sciences ecosystem. Grove AI's team and technology now form a core pillar of Hippocratic AI's Life Sciences Division. Over the past year, Grove AI's platform supported more than 10 million patient interactions, uncovering opportunities to automate and transform thousands of slow, manual workflows across clinical research and development. "At Grove AI, we built the leading agentic AI solution for pharma R&D by working directly with clinical teams and patients at scale," said Tran Le, Co-Founder of Grove AI. "By joining Hippocratic AI, we can build on that foundation and accelerate the delivery of these capabilities to a much broader set of life sciences organizations, combining our innovation with Hippocratic AI's enterprise scale." The acquisition brings two cornerstone offerings to Hippocratic AI's life sciences portfolio: * AI Agent ("Grace"): an always-on, multilingual AI agent that supports end-to-end patient engagement, recruitment, and follow-up across voice, text, and email. * Grove AI PRM(TM)(Participant Relationship Management): a purpose-built platform that orchestrates AI-driven participant interactions with full transparency, human oversight, and regulatory alignment. "With our combined expertise, Hippocratic AI and Grove AI are uniquely positioned to lead the agentic AI transformation at a critical inflection point for the life sciences industry," said Sohit Gatiganti, Co-Founder of Grove AI. Today, the combined team is actively collaborating with five of the world's leading global pharmaceutical companies to deploy AI agents for patient and provider engagement at enterprise scale. Launch of Life Sciences Executive Advisory Panel To guide product development and ensure real-world relevance, Hippocratic AI has convened a Life Sciences Executive Advisory Panel, featuring seasoned leaders from the world's most respected pharmaceutical and medical device companies: * Jim Meyers, former Chief Commercial Officer at Gilead Sciences, who led the launch of 24 products, including 11 blockbuster brands. * Michael Norton, former VP of Global Medical Affairs at AbbVie, with over 20 years in R&D and medical leadership across AbbVie and Abbott. * David Pierce, former President of MedSurg, Endoscopy, and Urology at Boston Scientific, where he helped grow the company to over $20B in revenue. * Richard Klausner, former Director of the National Cancer Institute, former Executive Director at the Gates Foundation, and Co-founder of Altos Labs, a leading biotechnology company with more than $3 billion in funding, as well as Lyell Immunopharma, Juno Therapeutics, and Grail. This executive advisory panel brings deep expertise across therapeutic areas, commercialization, medical affairs, quality, and device innovation, ensuring Hippocratic AI's offerings are tuned to the evolving needs of life sciences partners. "I decided to join Hippocratic AI as an advisor due to the team's commitment to innovation that puts the patient and patient safety first. Their proven track record of supporting millions of patient clinical calls, powered by the Polaris Constellation Architecture, uniquely positions them to continue to drive meaningful change across life sciences. I am excited to apply my extensive industry experience during this pivotal period to help deepen the company's vertical expertise and navigate this complex landscape," said Jim Meyers, former Chief Commercial Officer at Gilead Sciences. Newly Appointed President of Life Sciences Leading the Life Sciences Division is Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. A former NHS surgeon and member of the UK General Medical Council's Quality Assurance Board, Dr. Wahid brings deep expertise in patient safety and regulatory rigor. He later spent a decade as a Partner at Boston Consulting Group, where he led global AI and healthcare transformation initiatives and advised executive teams and boards at more than 30 of the world's leading healthcare organizations. At Hippocratic AI, Dr. Wahid applies this combined clinical and strategic perspective to ensure AI adoption enhances care delivery while meeting the highest safety standards. "Hippocratic AI is building what life sciences has been waiting for: generative AI that can scale globally without compromising safety or regulatory integrity. The acquisition of Grove AI, combined with our expanded leadership team, advisory council, and collaboration with BCG, gives us the foundation to further operationalize agentic AI across research, clinical, and patient engagement workflows. My focus is ensuring these technologies are deployed responsibly, measurably, and at enterprise scale so innovation translates into real outcomes for patients and organizations alike," said Dr. Ahad Wahid, M.D., President of Life Sciences at Hippocratic AI. Strategic Collaboration with Boston Consulting Group As previously announced last week, Hippocratic AI has entered into a strategic collaboration with Boston Consulting Group (BCG) and BCG X to help pharma and medtech clients adopt generative AI solutions aligned with commercial, R&D, and medical affairs goals. Life sciences requires a strategic roadmap and deep understanding of regulatory requirements. BCG and Hippocratic AI will collaborate to bring integrated AI strategies, implementation services, and measurable ROI to the life sciences sector. This collaboration builds on BCG's AI transformation leadership and Hippocratic AI's pioneering generative AI healthcare agents, which are designed for safety, patient trust, and scale. "This collaboration is about closing the value gap in the industry by bringing together Hippocratic AI's sophisticated AI agent platform, BCG's strategy and governance expertise, and BCG X's Health Care Commercial AI solution to help clients turn potential into measurable business value," said Ashkan Afhkami, BCG managing director and senior partner and global leader for the Health Care practice at BCG X. About Hippocratic AI Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/.
Hippocratic AI, a leader in patient-facing generative AI healthcare agents, has acquired Grove AI and announced key strategic moves to expand its life sciences business. The company has appointed Dr Ahad Wahid as President of Life Sciences, launched a Life Sciences Executive Advisory Council, and entered a strategic collaboration with Boston Consulting Group. Grove AI's platform, which supported over 10 million patient interactions in the past year, will form a core pillar of Hippocratic AI's Life Sciences Division. The acquisition brings AI-driven patient engagement tools for clinical trials and R&D workflows. The advisory panel includes former executives from Gilead Sciences, AbbVie and Boston Scientific. Hippocratic AI has raised $404 million to date and currently supports 150 million clinical interactions, working with five major global pharmaceutical companies.
Anthropic, Genmab partner to use Claude for R&D and more digital health news. Hippocratic AI partners with Boston Consulting Group, and Verana Health merges with COTA. AI safety and research company Anthropic is partnering with international biotech company Genmab to build custom Claude-powered agentic AI capabilities aligned with Genmab's research and development processes. Anthropic's AI assistant and large language model (LLM), Claude, will be used by Genmab's team for data processing, analysis and document generation, with human oversight and guardrails, to assist with operational activities and improve consistency within clinical programs. "Clinical development is critical, heavily regulated and directly tied to patient outcomes. This is why we're partnering with an innovative and patient-focused biotech company like Genmab as they apply AI to support their clinical development process," Kate Jensen, head of Americas at Anthropic, said in a statement. "We're working closely with Genmab to deploy Claude and build custom agentic solutions with the intention to help their team focus on the hard problems that require human expertise and get therapies to patients faster." Hippocratic AI, a generative AI company focused on administrative healthcare tasks, is partnering with global consulting firm Boston Consulting Group (BCG) to help the biopharma and medtech industries implement generative AI healthcare agents. Hippocratic AI's generative AI focuses on nondiagnostic healthcare tasks such as medication onboarding, monthly reconciliation, answering hospital and payer policy questions, and providing EHR assistance. The companies said the partnership will combine Hippocratic AI's and BCG's expertise to help life sciences organizations generate value from AI technology and move from experimentation to enterprise-scale impact. "Our collaboration with BCG is built on a shared commitment to improving patient outcomes," Munjal Shah, founder and CEO of Hippocratic AI, said in a statement. "By combining BCG's deep strategic and operational expertise with our safety-focused generative AI health care agents, we can accelerate innovation across biopharma and medtech, bringing scalable, empathetic, and clinically aligned support to patients, providers, and researchers around the world." Real-world clinical data analytics company Verana Health has merged with oncology-focused data company COTA. Verana Health combines clinical expertise with real-world data to help providers access real-world evidence and obtain clinical insights. COTA focuses specifically on cancer care data, offering oncology research and development, regulatory, commercial, and health economics and outcomes research (HEOR) teams with patient data to help discover new treatment protocols for cancer care. Verana said in a statement that the merger adds high-fidelity oncology datasets and analytics to its offerings and strengthens its relationships within the biopharma industry, as the combined company will serve 17 of the top 20 global biopharma companies. "This is a unique opportunity to better serve organizations with advanced curation technology and real-world insights across multiple specialty therapeutic areas. This combination raises the bar for clinical expertise, data quality, validation, and transparency, so our partners can generate evidence with the utmost confidence," Sujay Jadhav, CEO of Verana Health, said in a statement.
CTG partners with Hippocratic AI to bring safe, patient-focused agentic AI to U.S. Healthcare organizations. CTG, a Cegeka company delivering IT and business solutions that enhance clients' digital agility, announced today a strategic partnership with Hippocratic AI, the global leader and pioneer of safety-focused, patient-facing clinical generative AI agents for healthcare. CTG is proud to offer managed AI and transformational consulting services to expand the implementation of Hippocratic AI's solution in the U.S. market. CTG brings decades of experience optimizing EHR, ERP, and clinical workflows, making it uniquely positioned to help healthcare organizations realize the full potential of Hippocratic AI through its managed services, performance improvement, and digital transformation expertise. Hippocratic AI was founded with a mission to achieve healthcare abundance by improving outcomes and reducing strain on the healthcare system through clinically safe AI agents. True to its namesake, Do No Harm, Hippocratic AI places patient safety above all else. Its patented Polaris Safety Constellation Architecture has been clinically tested and validated through a network of more than 7,000 licensed U.S. clinicians and has completed over 500,000 test calls, setting a new benchmark for safe, scalable, and clinically sound AI. The company's AI agents have surpassed 115 million real-world patient interactions. Serving providers, payers, and life science organizations, Hippocratic AI's generative AI agents power more than 1,000 use cases showcasing quality improvement, care management, readmission reduction, health equity, compliance, and preventive care, to name a few. Hippocratic AI is pioneering a new standard for healthcare AI agents, powered by rigorously clinically tested large language models (LLMs) to engage patients and providers. Through this partnership, CTG and Hippocratic AI will empower healthcare organizations to: * Scale patient outreach and increase care team capacity * Support at-risk patients with timely follow-up and care coordination * Improve care team efficiency by independently managing routine clinical conversations and sending urgent (red) escalations in real time to nurses * Boost clinical readiness for upcoming appointments, procedures, and surgeries with automated reminders * Execute health campaigns for preventative screenings, immunizations, and public health alerts * Close care gaps with multilingual AI agents that deliver a personalized, patient-centric experience "Healthcare organizations are under extraordinary pressure to do more with less, expanding access, closing care gaps, and improving patient engagement," said Dan Stoke, Vice President of Healthcare at CTG. "Through this partnership, we're equipping our clients with innovative AI-driven solutions that extend the reach of clinical teams, enhance patient experience, and expand access to care across the care continuum, all while maintaining an unwavering commitment to patient safety." "Our partnership with CTG supports Hippocratic AI's mission to bring safe, clinically validated generative AI into healthcare at scale," said Bill Hudson, Chief Information Officer at Hippocratic AI. "CTG's leadership in healthcare IT and digital transformation makes them the ideal implementation partner as we work together to improve patient access, reduce administrative burden, and ensure patients receive timely, high-quality touchpoints that improve patient lives." CTG and Hippocratic AI are jointly developing an AI agent that transforms routine patient support into meaningful clinical engagement. This next-generation agent is designed to assist patients with accessing their records through the patient's health portal. This innovative solution reimagines routine support calls, such as password resets or help locating test results, as opportunities for meaningful clinical engagement. Rather than routing patients through multiple teams, the AI agent is trained to recognize and act on potential clinical needs in real-time. For example, if a patient calls to retrieve test results, the agent can automatically help schedule follow-up appointments or close care gaps based on those results. By embedding clinical intelligence into everyday support experiences, CTG and Hippocratic AI are helping healthcare organizations turn ordinary support moments into compassionate, personalized care connections. CTG, a Cegeka company, delivers IT and business solutions that enhance clients' digital agility, empowering them to seize new opportunities and overcome challenges. Our expertise, grounded in more than 55 years' experience, drives data-driven decisions, boosts business performance, enhances client experiences, fosters continuous innovation, and elevates cyber resilience. CTG combines local Americas market knowledge with the global expertise of over 10,000 Cegeka Group team members in more than 17 countries to provide innovative, tailored solutions. Together, we operate across the Americas, Europe, and India, working with over 3,000 clients in high-growth industries. CTG is a Great Place to Work Certifiedtm company. Visit www.ctg.com. About Hippocratic AI Hippocratic AI has developed the safest generative AI Agents for healthcare. The company believes that generative AI has the ability to bring healthcare abundance to every person in the world. The company focuses on building non-diagnostic patient-facing clinical AI agents and does not allow its agents to be used to prescribe or diagnose. Hippocratic AI has received a total of $404 million in funding and is backed by leading investors, including Andreessen Horowitz, General Catalyst, Kleiner Perkins, Avenir, NVIDIA's NVentures, Premji Invest, SV Angel, Google's CapitalG, and numerous health systems. Learn more at https://hippocraticai.com/. | these press releases may also interest you | at 08:30 | lendingpoint announces strategic capital raise to accelerate growth in 2026 and beyond | | / | lendingpoint, the award winning, AI-driven fintech facilitating consumer credit origination and loan servicing, today announced a new round of capital financing that positions the company for significant expansion and market acceleration in 2026... | | 14 nov 2025 | avicanna reports Q3 2025 | | / | avicanna inc. ("avicanna" or "company") a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q3 2025. Management... | | 14 nov 2025 | COSCIENS biopharma inc. announces leadership change | | / | COSCIENS biopharma inc. (FINRA: CSCIF) ("COSCIENS" or the "company"), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that peter H. Puccetti, CFA, chairman of the company's board of directors (the... | | 14 nov 2025 | university of phoenix college of doctoral studies researchers present on harnessing generative AI tools for student engagement at 2025 AECT international convention | | / | researchers from the university of phoenix college of doctoral studies center for educational and instructional technology research (CEITR) presented "transforming higher education: harnessing generative AI for student engagement" at the 2025... | | 14 nov 2025 | repare therapeutics enters into definitive agreement to be acquired by xenotherapeutics, inc. | | / | repare therapeutics inc. ("repare" or the "company"), a clinical-stage precision oncology company, today announced that it has entered into a definitive arrangement agreement (the "arrangement agreement") with xenotherapeutics, inc. and xeno... | | 14 nov 2025 | elastic named a leader in 2025 IDC marketscape for worldwide observability platforms | | / | elastic, the search AI company, has been named a leader in the IDC marketscape: worldwide observability platforms 2025 vendor assessment (doc #US53004325, november 2025). According to the IDC marketscape report, "elastic's overarching strength is... | | / | more news about science and technology... News published on 10 november 2025 at 10:55 and distributed by: